Enliven Therapeutics Q2 EPS $(0.49) Beats $(0.54) Estimate

Enliven Therapeutics (NASDAQ: ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.54) by 9.26 percent. This is a 19.51 percent decrease over losses of $(0.41) per share from the same period last year.